Bel­lus hopes to fu­el up on IPO cash as it squares off with gi­ant Mer­ck on a ri­val drug

Fu­eled by a suc­cess­ful Phase I tri­al treat­ing chron­ic cough and lured by the promise of tak­ing their lead drug to oth­er ap­pli­ca­tions, Mon­tre­al-based Bel­lus …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER